July 14, 2024

Rising Prevalence Of Organ Transplantation To Boost The Growth Of Calcineurin Inhibitor Market

Market Overview:

Calcineurin inhibitors are immunosuppressive drugs that work by inhibiting calcineurin, an enzyme that helps signal T-cells to become active. The drugs are commonly used as maintenance therapy after kidney, heart or liver transplant surgeries to reduce the risk of organ rejection. The two main calcineurin inhibitors are cyclosporine and tacrolimus which help prevent the immune system from attacking and damaging the transplanted organ. Calcineurin inhibitors have revolutionized organ transplantation by dramatically improving short- and long-term patient and graft survival rates.

Market key trends:

One of the key trends in the calcineurin inhibitor market is the rising prevalence of end-stage renal disease (ESRD) and organ failure cases globally. ESRD causes total and permanent kidney failure which can only be treated through kidney transplantation. According to data by the National Kidney Foundation, nearly 800,000 people in the U.S. have irreversible kidney failure. Additionally, the growing elderly population worldwide is also fueling the number of organ failure cases as older people are more prone to chronic health conditions. This substantial patient pool creates sustained demand for calcineurin inhibitors for organ transplant patients. Furthermore, continuous technological advancements are helping improve transplant success rates and long-term outcomes, thereby benefitting market growth over the forecast period.

Porter’s Analysis

Threat of new entrants: The biotechnology and pharmaceutical industries require substantial R&D investments and regulatory approvals to enter the market, thereby representing medium to high entry barriers.

Bargaining power of buyers: The bargaining power of buyers is moderate. The availability of generic substitutes and the involvement of regulatory authorities in price negotiations enable buyers to exert some pressure.

Bargaining power of suppliers: The key raw material suppliers possess moderate bargaining power due to the availability of substitutes and the fragmented nature of suppliers.

Threat of new substitutes: The threat of new substitutes is medium as research continues on developing novel treatment options for conditions currently managed by calcineurin inhibitors.

Competitive rivalry: Strong competitive rivalry exists among the existing market players.

Key Takeaways:

The Global Calcineurin Inhibitor Market Demand  is expected to witness a CAGR of 10% over the forecast period, due to increasing prevalence of autoimmune diseases and post-organ transplant complications.

Regional analysis: North America dominates the global market and is expected to maintain its lead over the forecast period, owing to rising healthcare spending and growing organ transplantation procedures in the region. The Asia Pacific market is projected to exhibit the fastest growth rate during the study period, attributed to increasing healthcare infrastructure and spending.

Key players: Key players operating in the calcineurin inhibitor market include Novartis AG, Astellas Pharma Inc., LEO Pharma A/S, Allergan, Inc., Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Roche Holding AG, Bristol Myers Squibb Company, AbbVie Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Mylan N.V.


  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it